POTASSIUM CHLORIDE | N017476 | NOVARTIS PHARMACEUTICALS CORP
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
ATTACHMENT 2 HIGHLIGHTS OF PRESCRIBING INFORMATION K-TAB (potassium chloride)... FDA-2020-P-2005 The law firm Hyman, Phelps & McNamara, P.C. filed a suitability petition regarding K-TAB (potassium chloride) extended-release tablets. The petition requested FDA evaluation of the suitability of this product, though the specific regulatory action sought is not detailed in the provided text excerpt. | Suitability | 2020-09-23 | Open | HYMAN |
ATTACHMENT 3 HIGHLIGHTS OF PRESCRIBING INFORMATION POTASSIUM CHLORIDE extende... FDA-2020-P-2005 Hyman, Phelps & McNamara, P.C. filed a suitability petition regarding potassium chloride extended-release tablets, requesting FDA evaluation of the appropriateness of the product formulation and regulatory pathway for approval or continued marketing of this potassium supplementation medication. | Suitability | 2020-09-23 | Open | HYMAN |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.